Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis

Apoptosis

Volumn 13, Issue 7, 2008, Pages 883-894

  Cheng, Ching Feng ^a,b,c   Juan, Shu Hui ^d   Chen, Jin Jer ^c   Chao, Ying Chi ^c   Chen, His Hsien ^d   Lian, Wei Shiung ^b,c   Lu, Chun Yi ^e   Chang, Chung I ^e   Chiu, Ted H ^a   Lin, Heng ^a,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Carboplatin; Cardiomyocytes; Cardiotoxicity; Reactive oxidative stress; Statin

Indexed keywords

ACETYLCYSTEINE; CARBOPLATIN; CASPASE 3; CASPASE 9; CYTOCHROME C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PROTEIN BCL XL; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG ANTAGONISM; ENZYME ACTIVITY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CARDIOMYOPATHIES; CARRIER PROTEINS; CASPASES; CELLS, CULTURED; ENZYME ACTIVATION; HEART; IN SITU NICK-END LABELING; LEUKOPENIA; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PRAVASTATIN; PROTO-ONCOGENE PROTEINS C-AKT; RATS; REACTIVE OXYGEN SPECIES;

MUS; RATTUS;

EID: 46549083150     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-008-0214-9     Document Type: Article

References (35)

1. Fujiwara K, Sakuragi N, Suzuki S et al (2003) First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long term follow up. Gynecol Oncol 90:637-643
2. Pivot X, Cals L, Cupissol D et al (2001) Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of head and neck. Oncology 60:66-71
3. Alberts DS (1995) Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 22:88-90
4. Husain K, Scott RB, Whitworth C et al (2001) Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. Hear Res 151:71-78
5. Tiersten A, Wo J, Jacobson C et al (2004) Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast 13:341-346
6. Husain K, Whitworth C, Hazelrigg S, Rybak L (2003) Carboplatin-induced oxidative injury in rat inferior colliculus. Int J Toxicol 22:335-342
7. Dhalla AK, Hill MF, Singal PK (1996) Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 28:506-514
8. Bergmann MW, Rechner C, Freund C et al (2004) Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3b and transcription factor b-catenin. J Mol Cell Cardiol 37:681-690
9. Hayashidani S, Tsutsui H, Shiomi T et al (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105:868-873
10. Yao HW, Mao LG, Zhu JP (2006) Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol 33:793-797
11. Fujio Y, Nguyen T, Wencker D et al (2002) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660-667
12. Lin H, Lin TN, Cheung WM et al (2002) Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 105:1962-1969
13. Piech A, Dessy C, Havaux X, Feron O, Balligand JJ (2003) Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res 57:456-467
14. Han Y, Chen YS, Liu Z et al (2006) Overexpression of HAX-1 protects cardiac myocytes from apoptosis through caspase-9 inhibition. Circ Res 99:415-423
15. Vafiadaki E, Sanoudou D, Arvanitis DA et al (2007) Phospholaban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. J Mol Biol 367:65-79
16. Husain K, Whitworth C, Somani SM, Rybak LP (2001) Carboplatin-induced oxidative stress in rat cochlea. Hear Res 159:14-22
17. Zver S, Zadnik V, Bunc M, Rogel P, Cernelc P, Kozelj M (2007) Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 85:408-414
18. Meinardi MT, van Veldhuisen DJ, Gietema JA et al (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746-2753
19. Ide T, Tsutsui H, Kinugawa S et al (1999) Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85:357-363
20. Spallarossa P, Garibaldi S, Altieri P et al (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846
21. Ferdinandy P, Danial H, Ambrus I et al (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87:241-247
22. Kang PM, Haunstetter A, Aoki H et al (2000) Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 87:118-125
23. Suzuki Y, Demoliere C, Kitamura D et al (1997) HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J Immunol 158:2736 2744
24. Wang H, Li M, Rinehart JJ, Zhang R (2004) Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 10:1633-1644
25. Boughattas NA, Levi F, Fournier C et al (1990) Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharmacol Exp Ther 255:672-679
26. Wang H, Li M, Rinehart JJ, Zhang R (2004) Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol 53:459-467
27. Iseri S, Ercan F, Gedik N, Yuksel M, Alican I (2007) Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology 12:256-264
28. Damrot J, Nubel T, Epe B, Roos WP, Kaina B, Fritz G (2006) Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol 149:988-997
29. Yamato M, Watanabe T, Higuchi K et al (2007) Anti-inflammatory effects of pravastatin on helicobacter pylori-induced gastritis in mice. Dig Dis Sci 52:2833-2839
30. Yao HW, Mao LG, Zhu JP (2006) Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol 33:793-797
31. Kozar K, Kaminski R, Legat M et al (2004) Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24:1149-1157
32. Cafforio P, Dammacco F, Gernone A, Silvestris F (2005) Stains activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26:883-891
33. Werner M, Sacher J, Hohenegger M (2004) Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol 143:715-724
34. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105:739-745
35. Feleszko W, Mlynarczuk I, Bakowiec-Iskra EZ et al (2000) Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6:2044-2052